台北, 2026年4月16日 - (亞太商訊 via SeaPRwire.com) - OBI Pharma, Inc.（TPEx:4174.TWO）今日宣佈將出席 AACR 2026 年會，並透過十篇海報展示其 GlycOBI® 平台的變革性潛力。傳統 ADC 常因隨機偶聯而受到限制，導致藥物與抗體比值（DAR）不均一、穩定性不足以及治療窗口狹窄。相比之下，OBI 的位點特異性糖鏈技術可實現高度均一的 DAR，從而帶來更優的 PK/PD 特徵，並降低脫靶毒性，這一點已在 OBI 的主要項目 OBI-902 和 OBI-904 中得到驗證。我們正透過新一代雙特異性（OBI-201）以及雙特異性雙載荷（OBI-221）ADC 推動精準腫瘤學的進一步發展。這些“以生物學驅動”的分子旨在克服腫瘤異質性和多藥耐藥性——這是當前癌症治療中的關鍵挑戰。透過結合 GlycOBI® 與 GlycOBI DUO® 平台，OBI 正在開發具有創新性和差異化的療法，以滿足難治性實體瘤患者尚未被滿足的醫療需求。此外，OBI 強大的 ADC 偶聯平台已被證明能夠穩定實現產品品質與可擴展性，同時支援向下一代治療模式拓展，包括降解劑-抗體偶聯物（DAC）。這些數據將於 2026 年 4 月 17 日至 22 日在美國加利福尼亞州聖地亞哥舉行的美國癌症研究協會（AACR）年會上展示。“在 OBI，我們致力於打造更優質的 ADC，”OBI Pharma 首席科學官陳雅琪博士表示。“我們的目標是提供不僅能夠更有效、更精準靶向腫瘤，同時還能減少副作用的療法，為患者帶來具有潛在改變生命意義的治療選擇。”2026年4月20日（星期一）（上午9:00 - 12:00）標題：透過 OBI-902 克服耐藥性：下一代 TROP2 ADC 的臨床前評估1 作者：Ren-Yu Hsu, Chi-Huan Lu, Chi-Sheng Shia, Jing-Rong Huang, Hsin-Shan Wu, Lu-Tzu Chen, Jhih-Jie Yang, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Ya-Chi Chen。OBI Pharma, Inc，台灣台北 會議主題：PO. ET07.01 - 定量藥理學與轉化建模 地點：海報區 17 海報編號：6 摘要編號：1818標題：OBI-904，一種靶向 Nectin-4 的下一代 Exatecan ADC，展現出增強的細胞毒性並克服 Enfortumab Vedotin 耐藥性2作者：Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen。OBI Pharma, Inc，台灣台北會議主題：PO.ET02.02 - 抗體藥物偶聯物與連接子工程 2 地點：海報區 13 海報編號：26 摘要編號：1729標題：OBI-904，一種基於糖鏈的位點特異性靶向 Nectin-4 的 ADC，在非臨床研究中展現出強效且持久的抗腫瘤活性，並具有改進的 PK 特徵及克服 EV 耐藥性的能力3 作者：Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen。OBI Pharma, Inc., 台灣台北會議主題：PO.ET07.01 - 定量藥理學與轉化建模 地點：海報區 17 海報編號：7 摘要編號：1819標題：具有雙載荷的 MET/HER3 抗體藥物偶聯物：一種消除腫瘤逃逸機制的雙靶點策略5 作者：Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Ting-Yu Chang, Hong-Syuan Lin, Cheng-Yen Wei, Shin-Jin Lin, Lu-Tzu Lu, Meng-Hsin Liu, Wei-Jhen Huang, Ya-Chi Chen。OBI Pharma, Inc., 台灣台北會議主題： PO.CL.0705 - 靶向抗原療法與免疫 地點：海報區 49 海報編號：17 摘要編號：2665標題：引導-效應 bsADC：透過協同內吞作用提升載荷遞送效率6作者：Wei-Jhen Huang, Woan Eng Chan, Meng-Hsin Liu, Yueh Chin Wu, Ya-Chi Chen。OBI Pharma, Inc., 台灣台北會議主題： PO.ET02.02 - 抗體藥物偶聯物與連接子工程 2 地點：海報區 13 海報編號：27 摘要編號：1730標題：親水性增強的連接子技術實現位點特異性的降解劑-抗體偶聯物，具有改進的穩定性和增強的活性7 作者：Yu-Hung Chen, Wei-Chien Tang, Chi-Dian Lu, Hung-Yi Lin, Wei-Jhen Huang, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang。OBI Pharma, Inc., 台灣台北會議主題：PO.ET02.02 - 抗體藥物偶聯物與連接子工程 2 地點：海報區 13 海報編號：28 摘要編號：1731標題：基於細胞的載荷釋放揭示雙載荷 ADC 中設計、位點及細胞依賴的比例變化8 作者：Nan-Hsuan Wang, Wei-Han Lee, Evelyn He, Li Chuan Huang, Yu-Chao Huang, David Teng-Yi Huang, Ya-Chi Chen。OBI Pharma, Inc., 台灣台北會議主題： PO.CH01.06 - 抗體、抗體藥物偶聯物與核酸 地點：海報區 38 海報編號：5 摘要編號：23972026 年 4 月 20 日（星期一）（下午 2:00 - 5:00）標題：TROP2 上調及其與 HER2 的相互作用介導曲妥珠單抗耐藥性4 作者：Yuan-Liang Wang, Chi-Huan Lu, Cheng-Yen Wei, Jye-Yu Huang, Woan-Eng Chan, Lu-Tzu Chen, Ya-Chi Chen。OBI Pharma, Inc., 台灣台北會議主題：PO.ET03.06 - 藥物耐藥性 1：抗體與 ADC 地點：海報區 12 海報編號：18 摘要編號：29722026 年 4 月 21 日（星期二）（上午 9:00 - 12:00）標題：基於糖鏈的位點特異性 ADC 透過改進的載荷遞送和免疫激活實現持續的腫瘤控制9 作者：Liu Chih-Chun, Tsai Yi-Chien, Huang Jing-Rong, Lo Fei-Yun, Pei Yu, Hsu Ren-Yu, Tu Tzu-Hsuan, Chen Ya-Chi。OBI Pharma, Inc., 台灣台北會議主題： PO.IM02.04 - 癌症中的適應性免疫 地點：海報區 6 海報編號：2 摘要編號：4234標題：透過新一代位點特異性糖鏈偶聯與雙載荷靈活性推進 ADC 治療的發展10 作者：Wei-Chien Tang, Yu-Hung Chen, Chih-Kang Chang, Ting-Wei Liu, Hung-Yi Lin, Wei-Jhen Huang, Chi-Huan Lu, Ren-Yu Hsu, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang。OBI Pharma, Inc., 台灣台北會議主題： PO.ET02.03 - 抗體藥物偶聯物與連接子工程 3 地點：海報區 12 海報編號：1 摘要編號：4423電子海報將於 4 月 17 日太平洋時間中午 12:00 起在 AACR 虛擬會議平台上線供瀏覽，同時也將於 4 月 18 日起在 OBI Pharma 官網（www.obipharma.com）上線。1 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/45832 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/53853 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/45884 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/50305 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/40516 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/54007 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/54018 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/64749 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/131110 AACR 2026 年年會摘要在線發布 https://www.abstractsonline.com/pp8/#!/21436/presentation/5403關於 OBI PharmaOBI Pharma 是一家處於臨床階段的全球腫瘤學公司，成立於 2002 年，總部位於台灣。公司與其子公司 OBI Pharma USA, Inc. 致力於開發創新癌症療法，為具有緊迫醫療需求的患者提供新的治療選擇。OBI 的研究重點是新型抗體藥物偶聯物（ADC）。透過其專有的下一代偶聯技術平台 Obrion™，OBI 建立了多樣化的 ADC 設計模式。該平台整合了專有的偶聯和連接子技術，包括 GlycOBI®、GlycOBI DUO®、EndoSymeOBI®、HYPrOBI®，以及新型不可逆半胱氨酸偶聯技術 ThiOBI®，以推進下一代 ADC 解決方案。OBI 已開發出一系列下一代 ADC 項目，包括單特異性 ADC，如處於 I 期臨床評估階段的 OBI-902（TROP2）和 OBI-904（Nectin-4）；雙特異性單載荷 ADC OBI-201（HER2 × TROP2）；以及雙特異性雙載荷 ADC OBI-221（cMET × HER3）。為拓展 HYPrOBI® 連接子技術的應用範圍，OBI 進一步開發了 ThiOBI® 技術，以實現不可逆的基於半胱氨酸的偶聯。除 ADC 項目外，OBI 的資產還包括 OBI-3424，這是一種類首創的小分子前藥，靶向 AKR1C3，可在醛酮還原酶 1C3 高表達的腫瘤中選擇性釋放強效 DNA 烷化劑。更多資訊請訪問 www.obipharma.com 。關於 OBI-902 和 OBI-992OBI-902 是一種靶向 TROP2 的抗體藥物偶聯物（ADC），攜帶強效拓撲異構酶 I 抑制劑載荷，以藥物-抗體比值（DAR）為 4 殺傷腫瘤細胞。TROP2 在多種實體瘤中高度表達，如乳腺癌、肺癌、膽道癌、膽管癌（膽管細胞癌）、卵巢癌、胃癌等多種癌症類型，因此成為理想的癌症治療靶點。OBI-902 是一種新型位點特異性糖鏈偶聯 ADC，採用 OBI 專有的 GlycOBI® 平台，具有更高的穩定性和更強的親水性。在多種腫瘤模型中（包括非小細胞肺癌、三陰性乳腺癌和胃癌），OBI-902 展現出顯著的抗腫瘤療效、改進的藥代動力學特徵以及良好的安全性。其 IND 已於 2025 年 4 月 30 日獲得美國食品藥品監督管理局（US FDA）批准，並分別於 2025 年 11 月 16 日和 12 月 5 日獲得膽管癌及胃癌（包括胃食管結合部癌）的孤兒藥資格認定。I/II 期臨床試驗（NCT07124117）正在進行中，I 期 a 部分預計於 2027 年上半年完成。OBI-992 是另一種靶向 TROP2 的抗體藥物偶聯物（ADC），透過基於半胱氨酸偶聯的親水性可酶切連接子，以藥物-抗體比值（DAR）為 4 攜帶強效拓撲異構酶 I 抑制劑載荷。OBI-992 在體循環中保持穩定，並將該細胞毒性載荷遞送至表達 TROP2 的腫瘤細胞，從而在避免脫靶毒性的同時實現腫瘤細胞殺傷。OBI-992 的 IND 申請已於 2024 年 1 月獲得美國 FDA 批准，並於 2024 年 8 月獲得用於治療胃癌（包括 GEJC）的孤兒藥資格認定。I/II 期研究（NCT06480240）已達到擬定的 II 期推薦劑量（pRP2D），I 期預計於 2027 年上半年完成。自 2021 年 12 月起，OBI 已獲得 Biosion, Inc.（www.biosion.com）授予的 TROP2 靶向抗體氨基酸序列在除中國大陸、香港和澳門以外所有地區的獨家許可。Biosion 在中國大陸、香港和澳門擁有該抗體序列的獨家權利。OBI 在除中國大陸、香港和澳門以外的所有地區擁有 OBI-992 和 OBI-902 的商業權利，而 Biosion 在中國大陸、香港和澳門擁有相應的商業權利。關於 OBI-904OBI-904 是一種抗體藥物偶聯物（ADC），由特異性靶向 Nectin-4（Nectin 細胞黏附分子 4）的單克隆抗體構成，透過 OBI 專有的 GlycOBI® ADC 賦能技術，並在雙功能酶 EndoSymeOBI® 和新型連接子 HYPrOBI® 的支援下，以藥物-抗體比值（DAR）為 8 偶聯強效拓撲異構酶 I 抑制劑載荷。該藥物有望成為同類首創及同類最佳的基於糖鏈的 ADC，旨在靶向多種表達 Nectin-4 的癌症類型。在多種動物疾病模型中（包括頭頸鱗癌、結直腸癌、三陰性乳腺癌、宮頸癌及肉瘤），其已顯示出抗腫瘤活性；在猴重複給藥毒性研究中，OBI-904 展現出良好的安全性，目前處於 IND 申請前開發階段。關於 OBI-201OBI-201 是一種 TROP2 × HER2 雙特異性 ADC，基於 OBI 的 GlycOBI® ADC 賦能技術構建，並偶聯拓撲異構酶 I 抑制劑。值得注意的是，OBI 首次證明 HER2 與 TROP2 可在細胞表面相互作用並形成蛋白複合物——這一突破性發現得益於與專業 AI 藥物研發合作夥伴的協作。與單特異性 TROP2 或 HER2 ADC 相比，OBI-201 具有多項優勢。透過同時靶向兩種抗原，它可擴大腫瘤覆蓋範圍，尤其適用於靶點表達異質性或表達水平較低的癌症。雙靶向可增強腫瘤選擇性、結合親和力及內吞作用，從而提高載荷向癌細胞的遞送效率，同時有望降低對正常細胞的毒性。OBI-201 還可能克服部分單特異性 ADC 治療後因靶點下調所產生的耐藥性。動物研究表明，在 HER2 表達極低的耐藥性乳腺癌模型中，OBI-201 相較於單靶點 ADC 展現出顯著更優的抗腫瘤活性。OBI-201 能夠持續抑制腫瘤生長，顯示出其克服多種耐藥機制的潛力。OBI-201 是一種新一代雙特異性 ADC，有望突破單靶點 ADC 的局限，為患者提供更全面且持久的治療選擇。關於 OBI-221OBI-221 是一種雙特異性雙載荷 ADC（BsDpADC），基於 OBI 的 GlycOBI DUO® 技術構建，靶向 cMET 和 HER3，並偶聯 MMAE 與拓撲異構酶 I 抑制劑雙載荷。在臨床實踐中，靶向 EGFR 的療法已成為治療非小細胞肺癌（NSCLC）和結直腸癌（CRC）的關鍵策略。然而，腫瘤常透過上調 cMET 和 HER3 快速產生耐藥性，從而維持腫瘤生長。此外，在胃癌、頭頸癌及多種其他實體瘤中也觀察到 cMET 和 HER3 的高表達，進一步凸顯了未被滿足的醫療需求。為應對這一挑戰，OBI Pharma 利用其專有的 GlycOBI DUO® 平台和 HYPrOBI® 連接子開發了新型雙特異性雙載荷抗體藥物偶聯物（BsDpADC）——OBI-221。該治療藥物可同時靶向 cMET 和 HER3，並遞送具有協同作用的細胞毒性載荷，從而有效對抗腫瘤耐藥性和異質性。這一突破性設計不僅滿足未被滿足的醫療需求，也代表了下一代 ADC 開發的前瞻性策略。OBI-221 在克服現有 EGFR 靶向療法耐藥性方面具有重要潛力，有望為患者提供更具針對性的治療選擇，並帶來顯著的臨床價值。關於 GlycOBI®OBI 開發了一種獨特的基於糖鏈的位點特異性 ADC 技術（GlycOBI®），採用即插即用（Plug and Play）設計，可兼容任意抗體、連接子和載荷，並支援多種藥物-抗體比值（DAR）（最高可達 16）。該技術由 OBI 專有的雙功能酶技術 EndoSymeOBI® 和親水性連接子技術 HYPrOBI® 驅動，作為 OBI Obrion™ ADC 技術體系的核心組成部分，能夠在 GMP 條件下透過高效、可規模化、流程簡化的兩步一鍋法偶聯工藝生成位點特異性且高度均一的 ADC。在偶聯過程中，GlycOBI® 避免破壞抗體結構，並確保生成的 ADC 保持與天然抗體相當的生物物理特性。此外，OBI 的連接子技術提高了載荷偶聯效率，並降低了聚集或降解的傾向，從而進一步支援穩定且可控的 ADC 生產過程。GlycOBI® 克服了傳統 ADC 方法常見的局限，並在多項體內研究中展現出更優的抗腫瘤活性和穩定性。值得注意的是，該平台支援偶聯細胞毒性小分子抑制劑以及高度疏水性的降解劑，從而拓展至包括 DAC 在內的下一代治療模式。關於 GlycOBI DUO®GlycOBI DUO® 是一種基於 GlycOBI® 位點特異性偶聯平台及其專有酶促偶聯策略構建的下一代雙載荷抗體藥物偶聯物（ADC）技術。該技術可在單一抗體上以可調比例精確、可編程地連接兩種不同載荷，並支援高 DAR 比值（最高可達 DAR24）。透過結合互補的作用機制，GlycOBI DUO® 旨在增強抗腫瘤療效、應對腫瘤異質性並提升整體治療指數，同時具備克服傳統 ADC 相關耐藥機制的潛力，代表了下一代 ADC 開發的重要進展。關於 ThiOBI®OBI 開發了一種新型不可逆半胱氨酸偶聯 ADC 平台（ThiOBI®），具有更高的穩定性，可適用於任意抗體、連接子和載荷。OBI 專有的 ThiOBI® 平台結合連接子技術（HYPrOBI®），可生成多種生物分子形式的 ADC，包括抗體片段、納米抗體、肽類和蛋白質。此外，OBI 的 HYPrOBI® 連接子技術提高了載荷的偶聯效率，降低了聚集傾向，並延長了 ADC 產品的半衰期。ThiOBI 克服了傳統半胱氨酸 ADC 的局限，並在多項體內研究中實現了更優的抗腫瘤活性和穩定性。GlycOBI®、EndoSymeOBI®、ThiOBI®、HYPrOBI® 和 GlycOBI DUO® 為 OBI 的註冊商標。Obrion™ 為正在申請註冊的商標。前瞻性聲明本新聞稿中非歷史事實的陳述屬於《1995 年私人證券訴訟改革法》所定義的前瞻性聲明。此類前瞻性聲明包括但不限於關於未來臨床試驗、試驗結果及其時間安排的陳述。相關風險因素已在 OBI Pharma 的報告和演示材料中不時披露，包括其向台灣證券期貨局提交的文件。公司聯絡人:Jukka MuhonenExecutive Director, Business DevelopmentOBI Pharma USA, Inc.1.617.821.0292 jukkamuhonen@obipharma.com來源: OBI Pharma USA, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BRISBANE, AUS, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide the latest progress update on the Graphene Aluminium-Ion Battery technology ("G+A CELLS") being developed by GMG and the University of Queensland ("UQ") under a Joint Development Agreement with Rio Tinto, one of the world's largest metals and mining groups, and with the support of the Battery Innovation Center of Indiana ("BIC") in the United States of America.The GMG G+A CELLS have now demonstrated superior performance characteristics when compared to a representative market leading ultra-fast charging batteries, the Lithium Titanate Oxide ("LTO") batteries, which can be sold at a premium price of up to US$1200/kWh.1Figure 1 shows the current energy density of G+A CELLS, based on BIC testing, and shows the doubling in performance (26 to 49 Wh/kg) since the previous announcement in December 20252 and in comparison, to a representative market leading fast charging high power LTO batteries.Figure 1: Increase in Energy Density for G+A CELLS since December '25 UpdateTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure1.jpgFigure 2 shows the charge and discharge curves for the G+A CELLS when charged in 6 minutes (10C) and 60 minutes (1C). The energy density of the cells for the G+A CELLS when charged in 60 minutes (1C) is now 101 Wh/kg when charging to 100% State of Charge (SOC) which is an increase from 58 Wh/kg from the previous update. This shows the G+A CELLS have a nominal voltage of approximately 3.2 Volts (an increase from 3.0 Volts in the previous update). The G+A CELLS maintained performance over hundreds of cycles at 6-minute fast charging rate (10C).Figure 2: Battery performance curves of G+A CELLS at 60 min and 6min charge (1C & 10C)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_001full.jpgBob Galyen, GMG Non-Executive Director and former CTO of CATL - the largest battery manufacturer in the world, commented: "With the possibility of charging from empty to full in around six minutes, this chemistry fundamentally changes how designers can think about electric vehicles, consumer electronics, and stationary storage. Instead of planning around long charge stops with large packs, engineers can optimise for rapid energy turnaround, with higher power, and safer, with GMG's battery made from abundant raw materials. Lithium-ion will remain a key part of the energy landscape for years to come, but its limitations in fast charging, temperature tolerance, and critical-mineral supply are increasingly evident. By leveraging aluminium and graphene, the GMG team is demonstrating a pathway to reduce reliance on traditional lithium-based systems and or combinatorial systems with multiple battery technologies while delivering step-change improvements in charge time and power density. This is not an incremental tweak to existing cells - it is a new platform that can open markets and use cases that were previously uneconomic or impractical. The companies that adapt quickest to this shift will lead the next wave of electrification, and GMG intends to be at the centre of that transition with graphene aluminium-ion technology."Standard commercial Lithium Nickel Manganese Cobalt ("LNMC") and Lithium Iron Phosphate ("LFP") battery cells for electric vehicles and stationary storage are NOT designed for continuous 6-minute charging (10C); typical recommended charge rates are ≤1 hour (1C), often 2 hours (0.5C), with only limited fast charge operation. Only specialized high-power cell designs like LTO battery cells can tolerate charge rates of 6 minutes (10C).3GMG has now developed a completely new hybrid electrolyte that is chloride free and non-corrosive, unlike common aluminium battery electrolytes, along with a complex cathode and anode technology that enables very stable fast charging over hundreds of cycles. The substrate for both the cathode and anode in the G+A CELLS is aluminium foil - which provides significant cost and weight savings compared with copper, the substrate material used in most lithium and sodium-ion batteries. GMG's technology does not include the use of lithium or copper. The Company has submitted an additional patent application covering these new developments.GMG believes that it has significantly met the key target specification requirements for use in heavy mobile equipment, as shown in Figure 3, its main targeted use case, including:- Charging in under 6 minutes;- Energy density > 100 Wh/kg after 1 hour of charging; and- Safe (no Lithium).The next battery development steps include the following activities:- Test and show cycle life up to 10,000 cycles- Test and show ambient temperature impacts- Test and show standard safety testing- Test and show no thermal battery management system needed Figure 3: G+A CELLS Battery Use Case - heavy mobile equipmentTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure3.jpgCraig Nicol, GMG Managing Director and CEO, commented: "This is a significant step up from where we were at with battery performance in December 2025 and we see the required performance for our targeted use case being largely met - which means we can start to put together the next stages of the battery maturation program - including partnerships and manufacturing plans."GMG management believes that the G+A CELLS can eventually achieve over 160 Wh/kg when charged in 1 hour, and over 80 Wh/kg when charged in 6 minutes with further development of the cathode, anode, electrolyte and component weights.Figure 4 shows the latest G+A CELLS in pouch format:Figure 4: Current Multi-Layer G+A CELLTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure4.jpgBattery Technology Readiness LevelThe battery technology readiness level ("BTRL") of the G+A CELLS remains at Level 4, whilst significantly progressed through this level as shown in Figure 5. GMG is currently in the process of completing the optimization of the electrochemical behaviour for the pouch cells via ongoing laboratory experimentation. Through collaboration with BIC, it is anticipated that the battery technology readiness will ultimately progress to BTRL 7 and 8 since the equipment and processes needed to produce the G+A CELLS are the same as those employed to make Lithium-Ion Batteries, though no definitive timeline for achievement can be provided at this time.Figure 5: Battery Technology Readiness Level (BTRL)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_004full.jpgThe Company is confident it can meet the overall timeline, as seen in Figure 6, of its battery cell roadmap that calls for testing of cells with customers in 2026 and small commercial production with support of various partners, including BIC, in 2027.Figure 6: Battery Cell RoadmapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_005full.jpgNext Steps Toward Commercialisation & Market ApplicationsJack Perkowski, GMG Non-Executive Chairman and Director, commented: "I am extremely proud that GMG has progressed its battery to this stage - the Company is getting very close to final commercialisation steps. We look forward to providing further updates as GMG progresses the development of its battery technology."The Company continues to see a broad range of potential applications for a completed G+A CELLS - utilising its ultra-high power-density and economic energy density characteristics. Along with Rio Tinto, a range of global companies have confidentially expressed their interest in working with GMG in the following vertical sectors:Figure 7: Market ApplicationsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_006full.jpgCurrently, GMG believes it will use a plastic battery pack design, similar to Figure 8, to hold the battery pouch cells - reducing the weight, cost and complexity relative to using a metal case. Using a plastic battery pack is possible for two main reasons - GMG believes that its battery will not require a thermal management system or the fireproofing precautions provided by the metal case in a lithium-ion battery. Using plastic will increase the comparative energy density of G+A CELL packs when compared to lithium-ion batteries.Figure 8: Expected Battery Pack for GMG's G+A CELLS Pouch FormatTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_007full.jpgComparison and Market Review: LTO Batteries As shown in Figure 9 below, the performance of GMG's G+A CELL technology is already very similar to representative LTO batteries.Figure 9: Comparison of GMG's G+A CELLS to Lithium Titanate Oxide (LTO) BatteryTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure9.jpg LTO batteries are sold at a premium to LFP and LNMC batteries, which are the main chemistries used in electric vehicles and energy storage systems, and are also widely used in other electronic applications due to their high performance and long cycle life. The material and manufacturing costs for G+A CELLS are expected to be similar to, or less than, the cost to manufacture standard lithium-ion batteries, but substantially lower than the costs to produce LTO batteries.LTO batteries have energy density ranging from 50 - 80 Wh/kg.6 The LTO product is sold globally for use in many applications — with a total of US$5.67 billion sales per annum in 2025. Sales of LTO batteries are expected to grow at 16.9% per annum to an estimated US$ 12.5 billion by 2030. The major manufacturers of LTO batteries include Toshiba, Gree, Microvast and CATL.Further details on applications for the LTO battery from Mordor Intelligence7 are described below. In many of the use cases for LTO batteries, GMG believes that its G+A CELLS can be substituted at a substantially lower cost.Commercial Vehicles: Automotive, primarily buses, refuse trucks, and drayage tractors rather than passenger cars, is the largest user of LTO batteries. Fleets realize five-year total-cost-of-ownership parity once fuel savings and lower maintenance offset higher upfront prices.Fast-charging Electric Buses and Trucks: Transit authorities need battery systems that accept repeated high-power "opportunity charges" during short layovers. LTO cells replenish 80% capacity in roughly five minutes, allowing operators to shrink fleet size without sacrificing route frequency. U.S. Low-No Emission Bus grants earmark more than US$1.5 billion per year, with bid specifications that explicitly reference rapid-charge capability. Parallel subsidy programs in China reimburse up to CNY 80,000 (US$ 11,396) per new-energy bus, accelerating volume deployment in provincial capitals.Hybrid and BEV: Regenerative braking and high-C-rate acceleration favour the use of LTO batteries. Use in fast-charge EV stations is growing rapidly as ride-hailing fleets adopt swap-ready models.Stationary Storage: Utility-scale batteries now cycle multiple times per day for frequency regulation, peak shaving, and voltage support. Energy-storage-system integrators adopt LTO batteries for grid-frequency response where state-of-charge swings are shallow but frequent.Industrial Robotics: LTO batteries are used in continuous-duty forklifts that require partial charges during operator breaks.Aerospace and Defense: Unmanned aerial vehicles, missile auxiliaries, and soldier-worn power banks operating from -40 °C to +60 °C ambient.5-minute Battery-Swap Stations: Battery-as-a-service platforms require ultra-fast turnaround and high cycle life. CATL confirmed plans to install 1,000 swap stations in 2025 and 30,000-40,000 by 2030, each requiring packs that tolerate thousands of rapid exchanges without degradation.Sub-10 kWh Packs: Cordless construction tools, autonomous ground vehicles, and medical carts select LTO batteries to bypass daily pack swaps.12V starter replacement to Lead acid: GMG's G+A CELLS battery technology would be a viable 12 V starter-battery replacement for lead-acid, offering lower weight, longer cycle life, good low-temperature performance and improved cold-cranking capability, together with excellent tolerance to storage at 0% state of charge. In suitable system designs, the chemistry's stable voltage behaviour can also reduce balancing requirements and simplify battery management, helping to lower overall system cost.Lifecycle Procurement Preference: Many government procurement frameworks now weigh lifecycle reliability higher than purchase price. For example, New Mexico awarded a US$ 400 million bus electrification contract that included stringent thermal-runaway resistance metrics. Europe's Clean Industrial Deal allocates capital for storage technologies that stabilize renewables, aligning well with LTO batteries' fast-response profile.Cylindrical Cells: accounted for 37.7% of LTO battery sales in 2024 as entrenched production lines and robust steel casings satisfied heavy-duty demand. Pouch designs address aerospace weight requirements and constrained dashboards in autonomous robots.Summary of Important Milestones for GMG's G+A CELLS Development: MonthImportant Milestones in the Development of the Graphene Aluminium Ion BatteryMay 2020GMG and UQ win Australian Research Council grant for Graphene battery developmenthttps://graphenemg.com/gmg-and-uq-wins-australian-research-council-grant-for-graphene-aluminium-ion-battery-development/Apr 2021The University of Queensland and GMG kick off coin cell battery development projecthttps://graphenemg.com/gmg-the-university-of-queensland-research-uni-quest-kick-off-the-graphene-enhanced-aluminium-ion-battery-development-project/May 2021Graphene aluminium-ion battery performance data - Energy Density and Power Densityhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-performance-data/Jun 2021Graphene aluminium-ion battery performance data - Cycle Lifehttps://graphenemg.com/graphene-aluminium-ion-battery-performance-data/Jun 2021Significant potential battery customer market response to launch of batteryhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-progress-update/Jul 2021Investment decision for coin cell battery development centrehttps://graphenemg.com/gmg-battery-pilot-plant-investment/Oct 2021Construction starts for coin cell battery development centrehttps://graphenemg.com/construction-battery-pilotplant/Oct 2021Bosch Australia Manufacturing Solutions and GMG sign Letter of Intenthttps://graphenemg.com/gmg-and-bosch-sign-collaboration-arrangement-for-bosch-to-design-and-deliver-gmgs-graphene-aluminium-ion-battery-manufacturing-plant/Dec 2021Commencement coin cell battery development centrehttps://graphenemg.com/battery-pilot-plant/Dec 2021Initial coin cell batteries sent for customer feedbackhttps://graphenemg.com/graphene-aluminium-battery-customers-prototypes/Mar 2022Initial factory acceptance testing of semi-automated prototype battery cell assembly equipmenthttps://graphenemg.com/gmg-announces-initial-factory-acceptance-testing-of-semi-automated-prototype-battery-cell-assembly-equipment/Mar 2022Wood Engineering and GMG Sign a Letter of Intenthttps://graphenemg.com/gmg-and-wood-agree-collaboration-arrangement-for-wood-to-engineer-and-deliver-major-graphene-manufacturing-expansion-projects/May 2022Rio Tinto and GMG sign Letter of Intenthttps://graphenemg.com/gmg-riotinto-energysavings-battery/Jun 2022Commissioning of Pouch Cell Equipmenthttps://graphenemg.com/gmg-manufactures-first-pouch-cell/Jun 2022Bob Galyen, former chief technology officer of CATL, joins GMG technical advisory committee.https://graphenemg.com/gmg-technical-advisory-committee-leadership-team-additions-and-cfo-change/Aug 2022Investment decision for Phase 1 modular Graphene Production Planthttps://graphenemg.com/gmg-announces-phase-1-expansion-project-to-graphene-manufacturing-facility-for-energy-saving-products-and-batteries/Oct 2022Significant battery performance, cell and graphene production improvementshttps://graphenemg.com/gmgs-battery-update-significant-battery-performance-cell-and-graphene-production-improvements/Dec 2022Investment of $600k Battery Development Centrehttps://graphenemg.com/gmg-invests-au-600000-to-accelerate-battery-pouch-cell-customer-testing-development-in-2023/Feb 2023Australian Government Approval (AICIS) for production and sale of batteries.https://graphenemg.com/gmg-receives-regulatory-approval-to-enable-significant-commercial-sales/May 2023Battery Joint Development Agreement with Rio Tinto signedhttps://graphenemg.com/gmg-announces-battery-joint-development-agreement-with-rio-tinto/May 2023Battery Technology Readiness Level (BRTL) 2-3 reachedhttps://graphenemg.com/gmg-announces-battery-team-and-related-updates/May 2023Decision to switch to develop Pouch Cells (instead of Coin Cells)https://graphenemg.com/gmg-announces-battery-team-and-related-updates/Jul 2023Bob Galyen former chief technology officer of CATL joins GMG board of Directorshttps://graphenemg.com/graphene-manufacturing-group-appoints-former-chief-technology-officer-of-catl-limited-to-its-board-of-directors/Sep 2023Battery Pouch Cell Prototypes Multilayered Auto-Stacker Demonstrationhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-pouch-cell-prototypes-multilayered-auto-stacker-demonstration/Sep 2023Reaching 500 mAh capacity batteryhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Sep 2023Battery Technology Readiness Level (BRTL) 4 reachedhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Nov 2023Rio Tinto and GMG Partnership Video Launchedhttps://graphenemg.com/rio-tinto-gmg-battery-partnership-video-launch/Dec 2023Commissioning of modular Graphene Production Planthttps://graphenemg.com/graphene-manufacturing-group-commissions-modular-graphene-production-plant/Feb 20241000 mAh Capacity Reachedhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-1000-mah-capacity-reached-and-next-steps-toward-commercialisation/Mar 2024Graphene Manufacturing Group Secures AU$2 million Funding Grant from Queensland Government for Battery Pilot Planthttps://graphenemg.com/graphene-manufacturing-group-secures-au2-million-funding-grant-from-queensland-government-for-battery-pilot-plant/Aug 2024GMG's Graphene Aluminium-Ion Battery: Progress Update and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-progress-update-and-next-steps-toward-commercialisation/Mar 2025GMG's Graphene Aluminium-Ion Battery: Collaboration with World Leading USA Battery Innovation Centre and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-collaboration-with-world-leading-usa-battery-innovation-centre-and-next-steps-toward-commercialisation/Dec 2025GMG Unveils Graphene Aluminium-Ion Battery that Fully Charges in 6 minuteshttps://graphenemg.com/gmg-unveils-graphene-aluminium-ion-battery-that-fully-charges-in-6-minutes/ About BIC:BIC is a collaborative initiative designed to incorporate leadership from renowned universities, government agencies, and commercial enterprises. BIC is a public-private partnership and a not-for-profit organization focusing on the rapid development, testing and commercialization of safe, reliable and lightweight energy storage systems for defense and commercial customers. BIC is a unique organization that has been leading battery cell development for world leading battery companies for over 10 years and has carried out over 500 battery development projects.About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041www.graphenemg.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the pricing of LTO batteries, expectations for GMG G+AI batteries to achieve specification requirements for heavy mobile equipment, the lower cost to produce GMG G+AI batteries, expectations for GMG G+AI batteries in respect of charging time, stability, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system when development is completed, that the new hybrid electrolyte is chloride free and non-corrosive, that the cathode and anode technology employed enables very fast and stable charging, that GMG G+AI batteries provide significant cost and weight savings relative to copper, that G+AI batteries can achieve over 150 Wh/kg charged over 1 hour and 75 Wh/kg when charged over 6 minutes following further development of cathode, anode, electrolyte and component weights, that G+AI batteries will progress to BTRL 7 and 8, that the timeline for the battery cell roadmap is achievable, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and which offers weight, cost and complexity advantages to a metal case and increased energy density, expectations for the lack of a thermal management system or fireproofing precautions, expectations for material and manufacturing costs, expectations for sales of LTO batteries, expectations for G+AI batteries being substitutable for LTO batteries at lower cost, expectations that G+AI batteries are viable 12V starter battery replacements and the rationale therefor and the advantages of pouch design for aerospace weight requirements and constrained dashboards of autonomous robots.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions that GMG G+AI batteries can be produced at lower cost, as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries, the speed and stability of charging, that G+AI batteries will progress to BTRL 7 and 8, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and offer weight, cost and complexity advantages to a metal case and increased energy density, that the service agreement with the BIC will enable the Company to optimize its cell design and battery manufacturing equipment, and that the Company will be able to meet its overall timeline on the battery cell roadmap. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that GMG G+AI batteries cannot be produced at lower cost, or any of the assumptions as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries can not be achieved, G+AI batteries do not offer expected speed and stability of charging, that G+AI batteries will not progress to BTRL 7 and 8, that a range of global companies in a variety of industries will not be interested in working with GMG, that the battery pack design will not be plastic and not offer weight, cost and complexity advantages to a metal case and increased energy density, that the Company will not be able to optimize the electrochemical behaviour of the pouch cell through laboratory experimentation or at all, that the Company will not be able to meet its overall timeline on the battery cell roadmap, that the service agreement with the BIC will not enable the Company to optimize its cell design and battery manufacturing equipment and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 04, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.1 https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.2 https://graphenemg.com/gmg-unveils-graphene-aluminium-ion-battery-that-fully-charges-in-6-minutes/3 https://findingspress.org/article/21459-impact-of-charging-rates-on-electric-vehicle-batt4 High-power type cells | SCiB™ Rechargeable battery | Toshiba5 https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.6 https://www.grepow.com/blog/battery-energy-density.html7 Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends ReportTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/292641 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAIPEI, TW, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904.We are further advancing precision oncology through our next-generation bispecific (OBI-201) and bispecific, dual-payload (OBI-221) ADCs. These "biology - driven" molecules are designed to overcome tumor heterogeneity and multi-drug resistance-key challenges in current cancer treatment. By incorporating both the GlycOBI® and GlycOBI DUO® platforms, OBI is developing novel and differentiated therapeutics addressing the unmet medical need for patients with difficult-to-treat solid tumors. Additionally, OBI's robust ADC conjugation platform has proven to consistently deliver product quality and scalability, while enabling expansion into next-generation modalities, including degrader-antibody conjugates (DACs).These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 17 to 22, 2026 in San Diego, CA. (USA)."At OBI, we make better ADCs," said Dr. Ya-Chi Chen, Chief Scientific Officer OBI Pharma. "Our goal is to deliver therapies that not only target tumors more effectively and precisely, but also reduce side effects, giving patients potentially life-changing treatment options."Monday, April 20, 2026 (9:00 AM - 12:00 PM)Title: Overcoming Resistance with OBI-902: Preclinical Evaluation of a Next-Generation TROP2 ADC1Authors: Ren-Yu Hsu, Chi-Huan Lu, Chi-Sheng Shia, Jing-Rong Huang, Hsin-Shan Wu, Lu-Tzu Chen, Jhih-Jie Yang, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO. ET07.01 - Quantitative Pharmacology and Translational ModelingLocation: Poster Section 17Poster Board Number: 6Abstract Presentation Number: 1818Title: OBI-904, a Next-Generation Nectin-4-Targeting Exatecan ADC, Demonstrates Enhanced Cytotoxicity and Overcomes Enfortumab Vedotin Resistance2Authors :Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number: 26Abstract Presentation Number: 1729Title: OBI-904, a Glycan-based Site specific Nectin-4-Targeted ADC, Demonstrates Potent and Durable Antitumor Activity with an Improved PK Profile and Overcoming EV-Resistance in Non-Clinical Studies3Authors: Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET07.01 - Quantitative Pharmacology and Translational ModelingLocation: Poster Section 17Poster Board Number: 7Abstract Presentation Number: 1819Title: The MET/HER3 Antibody-Drug Conjugate with Dual Payload: A Dual-Target Approach to Eliminate Tumor Escape Mechanisms5Authors: Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Ting-Yu Chang, Hong-Syuan Lin, Cheng-Yen Wei, Shin-Jin Lin, Lu-Tzu Lu, Meng-Hsin Liu, Wei-Jhen Huang, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.CL.0705 - Targeted Antigen Therapies and ImmunityLocation: Poster Section 49Poster Board Number: 17Abstract Presentation Number: 2665Title: Guide-effector bsADCs: Driving co-endocytosis for enhanced payload delivery6Authors: Wei-Jhen Huang, Woan Eng Chan, Meng-Hsin Liu, Yueh Chin Wu, Ya-Chi Chen .OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number : 27Abstract Presentation Number: 1730Title: Hydrophilicity-Enhanced Linker Technology Enables Site-Specific Degrader-Antibody Conjugates with Improved Stability and Enhanced Activity7Authors: Yu-Hung Chen, Wei-Chien Tang, Chi-Dian Lu, Hung-Yi Lin, Wei-Jhen Huang, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number: 28Abstract Presentation Number: 1731Title: Cell-based payload release highlights design, site, and cell-dependent ratio shifts in dual-payload ADCs8Authors: Nan-Hsuan Wang, Wei-Han Lee, Evelyn He, Li Chuan Huang, Yu-Chao Huang, David Teng-Yi Huang, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.CH01.06 - Antibodies, Antibody-Drug Conjugates, and Nucleic AcidsLocation: Poster Section 38Poster Board Number: 5Abstract Presentation Number: 2397Monday, April 20, 2026 (2:00 PM - 5:00 PM)Title:TROP2 Upregulation and Interaction with HER2 Mediate Trastuzumab Resistance4Authors: Yuan-Liang Wang, Chi-Huan Lu, Cheng-Yen Wei, Jye-Yu Huang, Woan-Eng Chan, Lu-Tzu Chen, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET03.06 Drug Resistance 1: Antibodies and ADCsLocation: Poster Section 12Poster Board Number: 18Abstract Presentation Number: 2972Tuesday, April 21, 2026 (9:00 AM - 12:00 PM)Title: Glycan-based site specific ADC Achieves Sustained Tumor Control through Improved Payload Delivery and Immune Activation9Authors: Liu Chih-Chun, Tsai Yi-Chien, Huang Jing-Rong, Lo Fei-Yun, Pei Yu, Hsu Ren-Yu, Tu Tzu-Hsuan, Chen Ya-Chi. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.IM02.04 - Adaptive Immunity in CancerLocation: Poster Section 6Poster Board Number: 2Abstract Presentation Number: 4234Title: Advancing ADC therapeutics with next-generation site-specific glycan conjugation and dual-payload flexibility10Authors: Wei-Chien Tang, Yu-Hung Chen, Chih-Kang Chang, Ting-Wei Liu, Hung-Yi Lin, Wei-Jhen Huang, Chi-Huan Lu, Ren-Yu Hsu, Nan-Hsuan Wang, Ya-Chi Chen,Teng-Yi Huang. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.ET02.03 - Antibody-Drug Conjugates and Linker Engineering 3Location: Poster Section 12Poster Board Number: 1Abstract Presentation Number: 4423The e-posters will be available for browsing at the AACR virtual meeting platform beginning at 12:00 PM PT on April 17, as well as on the OBI Pharma website (www.obipharma.com) beginning on April 18.1 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/45832 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/53853 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/45884 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/50305 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/40516 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/54007 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/54018 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/64749 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/131110 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/5403About OBI PharmaOBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan. Together with its subsidiary OBI Pharma USA, Inc., the company is dedicated to developing innovative cancer therapeutics to provide new treatment options for patients with urgent medical needs.OBI's research efforts center on novel antibody-drug conjugates (ADC). Through its patented next-generation conjugation technology platform, Obrion™, OBI has established diverse ADC design modalities. The platform integrates proprietary conjugation and linker technologies, including GlycOBI®, GlycOBI DUO®, EndoSymeOBI®, HYPrOBI®, and the novel irreversible cysteine-conjugation technology ThiOBI® , to advance next-generation ADC solutions. OBI has developed a next-generation suite of ADC programs. These include monospecific ADCs such as OBI-902 (TROP2), which is under Ph1 clinical evaluation, and OBI-904 (Nectin-4); a bispecific single-payload ADC, OBI-201 (HER2 x TROP2); and a bispecific dual-payload ADC, OBI-221 (cMET x HER3). To broaden the applicability of the HYPrOBI® linker technology, OBI has further developed the ThiOBI® technology to enable irreversible cysteine-based conjugation. In addition to its ADC programs, OBI's assets include OBI-3424, a first-in-class AKR1C3-targeted small-molecule prodrug that selectively releases a potent DNA-alkylating agent in the presence of the aldo-keto reductase 1C3 enzyme, which is highly expressed in certain tumors. Additional information can be found at www.obipharma.com.About OBI-902 and OBI-992OBI-902 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload to kill tumor cells with a drug-antibody ratio (DAR) of 4. TROP2 is highly expressed in a variety of solid tumors such as breast, lung, biliary, bile duct (cholangiocarcinoma), ovarian, gastric, and many other cancer types, rendering it an ideal target for cancer therapy.OBI-902 is a novel site-specific glycan-conjugated ADC using OBI's proprietary GlycOBI® platform, which provides improved stability and enhanced hydrophilicity. OBI-902 demonstrated remarkable antitumor efficacy across multiple tumors, including NSCLC, triple-negative breast cancer (TNBC), and gastric cancer, improved pharmacokinetic characteristics, and a favorable safety profile in various animal models. The IND of OBI-902 was cleared by the United States Food and Drug Administration (US FDA) on April 30, 2025, received Orphan Drug Designation (ODD) from the US FDA for cholangiocarcinoma on Nov. 16, 2025, and gastric cancer (GC), including gastroesophageal junction cancer (GEJC) on December 5, 2025.The Phase 1/2 Study (NCT07124117) is ongoing, with completion of the Phase 1a portion targeted for 1H 2027.OBI-992 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload with drug-to-antibody ratio of 4 (DAR 4) via a cysteine conjugated, hydrophilic and enzyme-cleavable linker. OBI-992 remains stable in circulation and delivers this cytotoxic payload to TROP2-expressing tumor cells, leading to tumor cell death while avoiding off-target toxicities.The US FDA cleared the IND application for OBI-992 in Jan 2024 and subsequently granted Orphan Drug Designation for the treatment of gastric cancer, including GEJC in Aug 2024. The Phase 1/2 Study (NCT06480240) has reached the putative Recommended Phase 2 Dose (pRP2D) and Phase I completion is targeted for 1H 2027.Since December 2021, OBI has been granted by Biosion, Inc. (www.biosion.com) an exclusive license to a TROP2 targeting antibody amino acid sequence in all jurisdictions except Mainland China, Hong Kong and Macau. Biosion holds exclusive rights to that antibody sequence in Mainland China, Hong Kong and Macau. OBI holds commercial rights to OBI-992 and OBI-902 in all jurisdictions except Mainland China, Hong Kong and Macau, while Biosion holds commercial rights to OBI-992 and OBI-902 in Mainland China, Hong Kong and Macau.About OBI-904OBI-904 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody specifically targeting Nectin-4 (Nectin cell adhesion molecule 4), linked to a potent topoisomerase I inhibitor payload with Drug-to-Antibody Ratio of 8 (DAR8) through OBI's proprietary GlycOBI® ADC enabling technologies, powered by a dual-function enzyme, EndoSymeOBI®, and a novel linker, HYPrOBI®. It is a potentially first-in-class and best-in-class glycan-based ADC designed to target multiple cancer types that express Nectin-4. Antitumor activity has been shown across several animal disease models, including HNSCC, CRC, TNBC, cervical and sarcoma cancers; OBI-904 has demonstrated a favorable safety profile in a repeat dose toxicity study in monkeys, and is now in the pre-IND stage of development.About OBI-201OBI-201 is a TROP2 x HER2 bispecific ADC generated by OBI GlycOBI® ADC enabling technologies conjugated with a topoisomerase I inhibitor. Notably, OBI is the first to demonstrate that HER2 and TROP2 can interact and form a protein complex on the cell surface-a groundbreaking discovery facilitated through collaboration with a specialized AI drug discovery partner. OBI-201 offers several advantages over mono-specific TROP2 or HER2 ADCs. By targeting both antigens, it broadens tumor coverage, especially in cancers with heterogeneous or low expression of either target. Dual targeting can enhance tumor selectivity, binding avidity, and internalization, improving payload delivery to cancer cells while potentially reducing toxicity to normal cells. OBI-201 may overcome resistance associated with downregulation of targets after treatment by certain monospecific ADCs.Animal studies revealed that OBI-201 demonstrated significantly superior anti-tumor activity compared to single-target ADCs in drug-resistant breast cancer models with extremely low HER2 expression. OBI-201 was able to sustain tumor growth suppression, indicating its potential to overcome multiple drug-resistance mechanisms. OBI-201 is a next-generation bispecific ADC poised to break through the limitations of single-target ADCs, potentially offering patients a more comprehensive and durable treatment option.About OBI-221OBI-221 is a Bispecific-Dual Payload ADC (BsDpADC), generated by OBI GlycOBI DUO® technologies, targeting cMET and HER3, conjugated with dual payload of MMAE and topoisomerase I inhibitor.In clinical practice, EGFR-targeted therapies have become a key strategy for treating non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) patients. However, tumors often rapidly develop resistance by upregulating cMET and HER3 that, in turn, sustain tumor growth. Moreover, high expressions of cMET and HER3 have been observed in gastric cancer, head and neck cancer, and various other solid tumors, further underscoring the unmet medical needs.To address this challenge, OBI Pharma leverages its proprietary GlycOBI DUO® platform and HYPrOBI® linker to develop a novel bispecific dual-payload antibody-drug conjugate (BsDpADC)-OBI-221. This therapeutic agent simultaneously targets cMET and HER3 while delivering synergistic cytotoxic agents, effectively combating tumor resistance and heterogeneity. This breakthrough design not only addresses an unmet medical need but also represents a forward-looking strategy for next-generation ADC development.OBI-221 holds meaningful potential to overcome resistance to existing EGFR-targeted therapies, potentially offering patients more targeted treatment options while delivering substantial clinical value.About GlycOBI®OBI has developed a unique glycan-based, site-specific ADC technology (GlycOBI®), designed in a Plug and Play format that is compatible with any antibodies, linkers, and payloads, and supports various drug-antibody ratios (DAR)(up to 16). Powered by OBI's proprietary dual-function enzymatic technology EndoSymeOBI® and its hydrophilic linker technology HYPrOBI®, GlycOBI®, a core component of OBI's Obrion™ ADC technology family, enables the generation of site-specific and homogeneous ADCs through an efficient, scalable and streamlined two-step, one-pot conjugation process under GMP conditions.During the conjugation process, GlycOBI® avoids disrupting the antibody structure and ensures that the resulting ADC retains biophysical characteristics comparable to the native antibody. In addition, OBI's linker technology improves payload conjugation efficiency and reduces the propensity for aggregation or degradation, further supporting a stable and well-controlled ADC manufacturing process. GlycOBI® has overcome limitations commonly associated with traditional ADC approaches and has demonstrated improved antitumor activity and stability in various in vivo studies. Notably, the platform supports the conjugation of both cytotoxic small-molecule inhibitors and highly hydrophobic degraders, expanding its applicability to next-generation modalities such as DACs.About GlycOBI DUO®GlycOBI DUO® is a next-generation dual-payload antibody-drug conjugate (ADC) technology built on the GlycOBI® site-specific conjugation platform and its proprietary enzymatic conjugation strategy. It enables the precise and programmable attachment of two distinct payloads to a single antibody with tunable ratios and supports high DAR ratios, including up to DAR24. By combining complementary mechanisms of action, GlycOBI DUO® is designed to enhance antitumor efficacy, address tumor heterogeneity, and improve the overall therapeutic index, with the potential to overcome resistance mechanisms associated with conventional ADCs-representing a promising advancement in next-generation ADC development.About ThiOBI®OBI has developed a novel irreversible, cysteine conjugation ADC platform (ThiOBI®) with improved stability, which can apply to any antibodies, linkers, and payloads. OBI's proprietary ThiOBI® platform including linker technologies (HYPrOBI®) can generate ADCs in different biomolecular formats, including antibody fragments, nanobodies, peptides, and proteins. Furthermore, OBI's HYPrOBI® linker technology has improved conjugation efficiency of the payload and reduced aggregation propensity and also expanded the half-life of the ADC products. ThiOBI has overcome the limitations of traditional cysteine ADCs and achieved better antitumor activity and stability in various in vivo tests.GlycOBI®, EndoSymeOBI®, ThiOBI®, HYPrOBI®, and GlycOBI DUO® are registered trademarks of OBI. Obrion™ is a trademark under registration.Forward-Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.COMPANY CONTACT:Jukka MuhonenExecutive Director, Business DevelopmentOBI Pharma USA, Inc.1.617.821.0292jukkamuhonen@obipharma.comSOURCE: OBI Pharma USA, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月15日 - (亞太商訊 via SeaPRwire.com) - 品創控股有限公司（「品創控股」或「公司」，連同其附屬公司統稱為「集團」；股份代號：8066）欣然宣佈，集團全資附屬公司賽博幻境（香港）有限公司（「賽博幻境」）於今日隆重舉行《語音 AI 之 Echo 生態戰略全球啟幕盛典》，正式啟動其全球語音 AI 回聲生態系統（Echo Ecosystem，「回聲生態」）戰略，構建從語音數據採集、處理到商業應用的全鏈路閉環。此舉標誌著集團在人工智能語音數據服務領域的戰略佈局邁入全新階段，為集團深化 AI 業務轉型、打造長效增長曲線奠定堅實基礎。針對語音數據採集規模、質量與多樣性的行業困境，賽博幻境創造性推出區塊鏈遊戲與語音數據採集相結合的全新模式。用戶參與遊戲時，完成指定文本的語音錄製任務，既可享受遊戲樂趣，亦可獲得代幣激勵。該「遊戲化採集」模式，可大規模、高效率獲取覆蓋不同年齡、地域、口音與情感表達的真人語音數據，為構建多元化聲音數據庫提供穩定持續的來源。採集完成後，回聲平台透過專業清洗、標註與分類處理，將原始語音轉化為可直接用於 AI 訓練的結構化聲音數據庫。相關數據庫於 AI 數據市場以回聲代幣交易，供全球開發者及企業採購使用，形成「用戶參與採集 — 獲取代幣激勵 — 數據加工處理 — 市場交易流通 — 產業應用賦能」的完整價值鏈閉環。該模式不僅大幅降低語音 AI 開發門檻，更讓數據貢獻者、開發者及終端用戶共享語音 AI 發展所帶來的裨益。「語音 AI 不僅是技術，更是未來數字世界的入口。」賽博幻境首席執行官郭曉鵬先生在盛典上表示，「回聲生態致力於構建語音 AI 時代的基礎設施，透過去中心化的數據採集網絡和開放的聲音數據庫市場，我們將為全球 AI 開發者提供最豐富、最優質的聲音數據資源，推動語音 AI 技術在各行各業的快速落地和應用創新。」當前，人工智能技術加速滲透各行各業，人機對話已成為 AI 應用場景的核心交互方式。語音 AI 技術作為 AI 智能體不可或缺的組成部分，正成為連接人類與數字世界的入口。高品質、多元化的聲音數據庫是 AI 智能體強化訓練的核心基礎，語音 AI 技術發展已進入「數據驅動」新階段，優質聲音數據庫不僅可顯著提升語音合成的情感表現力、語音識別的場景適應性與對話系統的個性化能力，更成為語音 AI 產業發展的核心競爭力與先發優勢所在。品創控股銳意推動業務多元化佈局，把握數字經濟與人工智能產業的蓬勃商機，並憑藉前瞻性轉型，成功構建「私域電商營運 + AI 技術服務」雙輪驅動的業務架構。本次回聲生態全球啟動，是集團深化 AI 業務佈局、推動主營業務向 AI 數據服務轉型的關鍵里程碑。展望未來，集團將以賽博幻境為核心載體，持續深耕語音 AI 技術研發，拓展生態合作網絡，推動技術在智能客服、數字人、元宇宙、智能汽車等前沿領域深度融合；同時深化兩大業務協同效應，強化核心競爭力，推動業務高質量發展，把握全球 AI 產業廣闊機遇，致力為股東創造可持續長期回報。圖片說明 賽博幻境首席執行官郭曉鵬先生講解去中心化語音網絡的價值實現，彰顯品創控股推動語音 AI 技術在各行各業的快速落地和應用創新的決心。關於品創控股有限公司品創控股有限公司的使命是妥善運用公司所獲得的資本與獨特投資機會，為股東提供穩定的優渥收入與獲利。品創控股由六個主要事業部門組成，包括智能卡製造服務、電子商務、人工智能、投資服務、資源回收投資與媒體與娛樂投資，主要業務為生產及銷售智能卡、提供定製智能卡應用系統、私域電子商務平台營運、人工智能語音技術數據服務、提供財務及管理諮詢服務、廢舊金屬銷售及貿易、以及媒體與娛樂行業之投資。公司的總部位於香港，旗下控股公司與投資則遍佈大中華地區。關於賽博幻境（香港）有限公司賽博幻境（香港）有限公司是品創控股有限公司的全資子公司，專注於語音人工智能技術的研發與應用。賽博幻境致力於通過創新的生態模式，打造從數據采集、處理到商業落地的全鏈條語音AI解決方案，助力全球智能語音產業的發展。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - As artificial intelligence adoption accelerates across Southeast Asia, enterprises across the ASEAN region are increasingly establishing structured AI engineering practices to move from experimentation to production-scale deployment.According to Joseph Bosco, Partner Manager, APJ - Prof Services at Databricks, organisations across ASEAN are recognising that sustainable AI adoption depends not only on advanced models but also on robust engineering foundations that ensure reliability, governance and operational scalability.“The early phase of AI adoption focused heavily on experimentation and proofs of concept,” Bosco said. “Across Southeast Asia we are now seeing a shift towards AI engineering practices that prioritise data quality, governance and production readiness.”Markets such as Singapore, Indonesia, Vietnam, Malaysia and Thailand are witnessing strong momentum in enterprise AI adoption as organisations modernise their data infrastructure and invest in advanced analytics capabilities.Industry experts note that AI engineering is becoming a critical discipline that connects AI innovation with enterprise operations. This includes building scalable data pipelines, managing machine learning lifecycle processes and integrating AI systems into business workflows.“Building a model is only one part of the challenge,” Bosco said. “The real work lies in creating reliable data pipelines, managing model lifecycle and embedding AI into operational systems.”Across ASEAN, many enterprises continue to manage complex data environments spanning legacy systems, multiple cloud platforms and software-as-a-service applications. Consolidating these fragmented data sources into unified platforms is increasingly seen as a prerequisite for scaling AI initiatives.Technology partners and consulting firms across the region are responding by developing dedicated AI engineering practices that combine expertise in data engineering, machine learning, generative AI and governance frameworks.These capabilities are already being applied across key sectors including financial services, telecommunications, and manufacturing.Bosco noted that Southeast Asia’s rapidly expanding data economies are creating a particularly dynamic environment for AI engineering talent and innovation.“As organisations across ASEAN continue to invest in data transformation, AI engineering will become an essential capability that enables enterprises to operationalise AI safely and effectively,” he said. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com